EPISODE · Feb 21, 2012 · 8 MIN
The Rich Get Richer: Another Efficacious Option for Refractory Hairy Cell Leukemia
from Journal of Clinical Oncology (JCO) Podcast
This podcast reports on a phase I/II trial investigating novel anti-CD22, moxetumomab pasudotox, in the treatment of patients with refractory hairy cell leukemia, which demonstrated responses in the majority of patients at all dose levels.
NOW PLAYING
The Rich Get Richer: Another Efficacious Option for Refractory Hairy Cell Leukemia
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m